SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over potential sales impact. Traders disagree on whether Inovios treatment could challenge Precigens position or whether PAPZIMEOSs established commercial lead and full approval offer an advantage over the rivals accelerated approval and commercialization hurdles.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sonys stronger-than-expected quarterly results and raised full-year outlook are driving attention, alongside reports of an expanded share buyback. Traders welcomed the update and rebound, while some remain cautious about memory-cost pressure, gaming weakness, and the stocks difficulty sustaining gains.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 results and stronger-than-expected Q4 profit outlook are driving attention, with traders emphasizing subscriber growth, improving margins, and better ad trends despite revenue and EPS misses. The sharp rise has surprised skeptics, while bulls argue the forward guidance matters more than the quarters headline results.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00385003 USD and is up 3.25 over the last 24 hours. It is currently trading on 374 active market(s) with $20,884,591.23 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMYs weak price action amid a broader crypto downturn is driving discussion, with traders split between buying the dip and criticizing the tokens prolonged underperformance. Bulls point to JasmyChain, AI/data initiatives and ecosystem partnerships as potential longer-term utility, while skeptics question whether those developments will translate into meaningful adoption.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons better-than-expected third-quarter results, supported by strong refining performance, are driving attention. Traders are reacting positively to the earnings beat and heavy call activity, while some question whether unusually strong refining margins can last.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,174,495.43496562. The last known price of Ethereum is 2,241.26797415 USD and is down -0.51 over the last 24 hours. It is currently trading on 14214 active market(s) with $20,040,937,711.35 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

The reported record Binance hack is driving concern about crypto exchange security and possible selling pressure across the market, including Ethereum. Traders are split between expecting further downside as confidence and risk appetite weaken and viewing ETHs relative resilience and dip buying as signs the shock may be contained.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results beat expectations, with strong theme-park performance and improving streaming profitability driving a broadly constructive reaction and renewed analyst optimism. Some traders remain skeptical, pointing to the stocks long-running sluggishness and questioning whether the results can support a sustained re-rating.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume rally has put AMP in focus, though traders point to no confirmed new catalyst. Bulls see a breakout and connect the move to AMPs Flexa collateral role and Anvil developments, while skeptics call it another speculative pump and question whether adoption will translate into meaningful use.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,981,969 in circulation. The last known price of World Liberty Financial is 0.05006283 USD and is down -1.40 over the last 24 hours. It is currently trading on 491 active market(s) with $50,711,301.08 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI is drawing attention amid backlash over reported Trump-family crypto earnings and concerns that insiders monetized the project while token holders absorbed losses. Bulls counter that a potential bank charter and USD1-related utility could support the token, though confidence is divided and many traders remain skeptical.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON is drawing attention as traders react to a recent pullback, with some attributing weakness to a broader market or analog/automotive semiconductor slump and lingering inventory correction in its end markets. Views are mixed: some are buying the dip, while others expect further downside; options flow has included both calls and puts.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?

Equity

A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.

The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies

Cancer treatment is undergoing one of the most significant transformations in modern medical history.

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst...

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

Cg Oncology Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>The deal would mark a major role reversal for AstraZeneca, which rejected Pfizer’s 70 billion pound bid in 2014 and has since grown into an oncology powerhouse.</li><li>AstraZeneca could deepen its U.S. presence, while Bristol Myers could gain support against patent expirations.</li><li>AstraZeneca reported $14.1 billion in first-half cancer-drug revenue, and Bristol Myers emphasized Opdivo, Breyanzi, and ADCs.</li></ul>After the biotech sector's worst month in more than a year, a potential combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is putting oncology stocks back in focus.The&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 7% in July, marking its worst monthly performance since March 2025.<img src="https://news.stocktwits-cdn.com/xbi_524050cb07.png" alt="xbi.png"><h2 class="st-heading-2">Why Bristol Myers Fits AstraZeneca&nbsp;</h2>A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e9027253-e13c-460a-a4b1-f9047e5a6ca7?syn-25a6b1a6=1">reported</a> tie-up would create one of the world's largest pharma companies worth nearly $400 billion and unite two huge cancer-drug franchises spanning checkpoint inhibitors, lung cancer, blood cancers, and antibody-drug conjugates (ADCs).&nbsp;Twelve years ago, AstraZeneca was the takeover target after Pfizer launched a 70 billion pound bid that the former ultimately rejected under CEO Pascal Soriot. At the time, the company was grappling with late-stage pipeline disappointments. Today, AstraZeneca&nbsp;has turned into a buyer.The British drugmaker has grown into an oncology powerhouse with an ambitious goal of reaching $80 billion in annual revenue by 2030, compared with $58.7 billion last year. Nearly half of its revenue already comes from the U.S., making Bristol Myers an attractive way to deepen its commercial footprint in the world's largest pharma market. The transaction would also dwarf AstraZeneca's $39 billion Alexion acquisition in 2021, currently the biggest deal in its history. Even so, Soriot emphasized during last week's earnings call that AstraZeneca does not "need M&amp;A to deliver" its 2030 ambitions, underscoring that any transaction would be strategic rather than necessary.For Bristol Myers, the company is battling looming patent expirations and has struggled to convince investors that its $74 billion Celgene acquisition generated the expected long-term returns.&nbsp;<h2 class="st-heading-2">Oncology Takes Center Stage&nbsp;</h2>The timing of the report is notable as both companies highlighted in last week's earnings calls that cancer&nbsp;is their primary growth engine. AstraZeneca reported first-half oncology revenue of $14.1 billion, up 15%, driven by blockbuster medicines including Tagrisso, Calquence, Imfinzi, Enhertu and Datroway. Calquence surpassed $1 billion in quarterly sales for the first time, while Imfinzi and Imjudo revenue&nbsp;surged by 25%.AstraZeneca also highlighted positive Phase 3 data across bladder and gastric cancer, reinforcing AstraZeneca's stance that combining immunotherapy with ADCs could become a long-term growth driver.Meanwhile, Bristol Myers pointed to Opdivo, Breyanzi, its expanding hematology portfolio, and its ADC pipeline as pillars of growth. It also announced another Phase 3 lung-cancer study and said recent data boosted confidence in its ADC platform. CEO Chris Boerner also reiterated that business development remains a capital-allocation priority. "If those things come together and ideally continue to enable us to de-risk our near-term growth profile, we certainly have the financial flexibility and the capabilities to be in the mix," Boerner told investors.<h2 class="st-heading-2">Cancer-Drug Overlap Clouds The Deal</h2>The merger’s biggest attraction may also be its greatest obstacle. Bristol Myers’ Opdivo and AstraZeneca’s Imfinzi are rival checkpoint inhibitors used across lung cancer and other solid tumors, with both companies pushing into earlier treatment settings and combination regimens.That overlap is likely to draw antitrust scrutiny. BMO Capital Markets warned that the companies’ “significant business overlap” in oncology could lower the chances of a deal. However, any required divestitures, or decisions to cut overlapping pipeline programs, could create openings for competitors and smaller biotech firms.<h2 class="st-heading-2">Which Cancer Stocks Could Feel The Ripple Effects?</h2>Among retail favorites, ImmunityBio likely has the strongest connection to both companies. Its IL-15 agonist Anktiva has been studied with Bristol Myers’ Opdivo in the Quilt program and can complement checkpoint inhibitors by restoring immune-cell activity after resistance develops. The biotech firm also competes with AstraZeneca in bladder cancer, where both companies are pursuing bladder-preserving treatments in different patient populations.&nbsp;On the other hand, Sellas Life Sciences already has a clinical link to Bristol Myers. Its cancer vaccine, GPS, which targets a protein called WT1, was tested with Bristol Myers’ Opdivo in patients with malignant pleural mesothelioma, with Bristol Myers supplying the drug for the investigator-led study. GPS is now being evaluated in the Regal trial in acute myeloid leukemia (AML). Sellas is also developing SLS009, another treatment for hard-to-treat blood cancers, which is also an area where a combined AstraZeneca-Bristol Myers would already have expertise.Revolution Medicines is already working with Bristol Myers on a clinical trial combining Daraxonrasib, a drug that blocks cancer-driving RAS proteins, with BMS’ Navlimetostat. AstraZeneca has also been building its presence in the KRAS and RAS field, placing Revolution within an area of interest to both companies. CG Oncology, meanwhile, is developing Cretostimogene for bladder cancer in the same bladder-preservation market AstraZeneca is targeting with Imfinzi.&nbsp;Over the past year, XBI gained 72%, outperforming AZN’s 13% rise but trailing BMY’s 58% by a narrower margin. The biggest moves came from the smaller oncology stocks: SLS surged 530%, RVMD jumped 403%, IBRX rose 191%, and CGON gained 167%, all far outpacing the broader biotech ETF.&nbsp;<img src="https://news.stocktwits-cdn.com/cancer_stocks_9548cd4aaf.png" alt="cancer stocks.png"><h2 class="st-heading-2">How Do Retail Traders Feel About Cancer Stocks?</h2>Retail traders were most upbeat on the two large drugmakers. On Stocktwits, sentiment for BMY was ‘extremely bullish’ with ‘high’ message volume, while AZN and IBRX both drew ‘bullish’ sentiment amid ‘high’ chatter.Interest was more subdued elsewhere: SLS sentiment was ‘bearish’ with ‘low’ message volume, RVMD was ‘neutral’ with ‘low’ activity, and CGON was ‘neutral’ amid ‘normal’ message volume.One user&nbsp;<a href="https://stocktwits.com/kpopinvestor/message/660708093">said</a> that an AZN-BMY merger could create even more value by acquiring SLS, adding that Sellas’ GPS and SLS009 programs could potentially be combined with drugs such as Opdivo, Imfinzi, Tagrisso and other cancer treatments.<stembedurl>https://stocktwits.com/kpopinvestor/message/660708093</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/arnolddiver/message/660709098">said</a> that an AZN-BMY deal could increase ImmunityBio’s strategic appeal, as looming Opdivo patent losses may increase interest in Anktiva’s lung-cancer potential.&nbsp;<stembedurl>https://stocktwits.com/arnolddiver/message/660709098</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/default/equity/why-retail-traders-couldn-nott-take-their-eyes-off-these-stocks-last-week-aapl-msft-amzn-meta-tsla/cZoRDhIRJ5m">Why Retail Traders Couldn’t Take Their Eyes Off These Stocks Last Week: AAPL, MSFT, AMZN, META, TSLA&nbsp;</a>

The SPDR S&P Biotech ETF (XBI) fell 7% in July, marking its worst monthly performance since March 2025. | Image source: Getty Images

AstraZeneca PLC

Bristol-Myers Squibb Co.

ImmunityBio Inc

Revolution Medicines Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$64.68
Prev Close	$63.47
Open	$63.00
Dividend Yield	0.00%
50-Day Moving Average	$69.43
Beta	1.47
Avg. Volume	977,653.31
PE Ratio	-24.00

52-Week High	$80.97
52-Week Low	$35.80
Market Capitalization	$5.73B
EPS (Annual)	-$2.08
Price to Book	5.55
Revenue Per Employee	$28,450.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGON Fundamentals